Established in 2000 as a Singapore registered company, ES Cell International has been at the forefront of developing new human embryonic stem cell technology. Based in Singapore’s biomedical research hub, the Biopolis, the company is at the forefront of offering highly documented and purified human pluripotent and embryonic progenitor cell lines.
“ESI has developed the world’s first clinical grade hES cell lines that have been derived following the principles of current Good Manufacturing Practice (cGMP)”. In collaboration with its parent company BioTime, Inc., the company also manufactures products for the research product markets.
ESI also has a significant portfolio of Intellectual Property surrounding hESC-based technology and their differentiation toward various cell lineages. Our subsidiary, CellCure Neurosciences Ltd, based in Israel, is a world leader in the development of neural technology derived from hESCs.
- Chief Executive Officer: Michael D. West, Ph.D.
- Chief Operating Officer: Robert W. Peabody, CPA
- Accounting Manager: Simba Ndemera
Board of Directors
- Alfred Kingsley, J.D. -Chairman
- Michael D. West, Ph.D.
- Robert W. Peabody, CPA
- Wai-Ming YAP, LLB (Hons)
Investors and Commercial Partners
ESI has a wide array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. We welcome inquiries regarding academic and commercial collaborations.